Zheng Yuzhou, Shi Dongmei, Hao Xinzhong, Wang Hongliang. Application progress of fibroblast activation protein inhibitors PET/CT in non-tumor diseases[J]. Int J Radiat Med Nucl Med, 2024, 48(4): 262-266. DOI: 10.3760/cma.j.cn121381-202303016-00413
Citation: Zheng Yuzhou, Shi Dongmei, Hao Xinzhong, Wang Hongliang. Application progress of fibroblast activation protein inhibitors PET/CT in non-tumor diseases[J]. Int J Radiat Med Nucl Med, 2024, 48(4): 262-266. DOI: 10.3760/cma.j.cn121381-202303016-00413

Application progress of fibroblast activation protein inhibitors PET/CT in non-tumor diseases

  • Fibroblast activation protein (FAP) is a serine protease with dipeptidyl peptidase and endopeptidase activities, often overexpressed in tumor-associated fibroblasts. Currently, the use of radioisotope-labeled fibroblast activation protein inhibitors (FAPI) PET/CT in tumors has become a new hot spot in nuclear medicine research. However, FAP is also highly expressed in activated fibroblasts, and there has been some progress in the application of FAPI PET/CT in non-tumor diseases (such as myocardial infarction, interstitial pulmonary fibrosis diseases, and immunoglobulin G4-related diseases, etc), holding potential for in the early diagnosis and efficacy evaluation of these diseases. The authors review of the application and research progress of FAPI PET/CT in non-tumor diseases.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return